(Total Views: 751)
Posted On: 10/30/2020 1:17:30 PM
Post# of 148903
Jay's Perspective PPS from yahoof
A bit of perspective:
March 27, 2020 : CYDY enters the world of COVID = share price range $2.25 to $3.00
At that point in time, trials had not begun, no peer reviewed papers, no science advisory board, no proven MOA yet, NO BLA specialist on board yet, no distribution agreement yet, no talks with other countries yet, minimal media coverage if at all. All we had was coverage of 11 patients at Montefiore in Bronx, NY
October 30, 2020 - share price is $2.45 but we have completed a phase 2 m/m trial, more than half way through a phase 3 trial, a fully developed science advisory board, 2 peer reviewed papers, over 60 eIND's, a proven MOA, media coverage, discussions with multiple counties, a signed distribution agreement, manufacturing with Samsung, and a BLA specialist to close these HIV/ COVID indications over the next 6 to 12 months.
Yet...we are trading at $2.45?
Oversold to say the least as we speak.
Definitely way way way way undervalued.
Less
A bit of perspective:
March 27, 2020 : CYDY enters the world of COVID = share price range $2.25 to $3.00
At that point in time, trials had not begun, no peer reviewed papers, no science advisory board, no proven MOA yet, NO BLA specialist on board yet, no distribution agreement yet, no talks with other countries yet, minimal media coverage if at all. All we had was coverage of 11 patients at Montefiore in Bronx, NY
October 30, 2020 - share price is $2.45 but we have completed a phase 2 m/m trial, more than half way through a phase 3 trial, a fully developed science advisory board, 2 peer reviewed papers, over 60 eIND's, a proven MOA, media coverage, discussions with multiple counties, a signed distribution agreement, manufacturing with Samsung, and a BLA specialist to close these HIV/ COVID indications over the next 6 to 12 months.
Yet...we are trading at $2.45?
Oversold to say the least as we speak.
Definitely way way way way undervalued.
Less
(8)
(0)Scroll down for more posts ▼
